Drugs / Gemigliptin
Trials 39 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 122 trials | ||||||
| Phase 1 | NCT07396844 | Jul 2026 overdue | — | LG Chem | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07399470 | Jan → Feb 2026 overdue | — | LG Chem | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07333742 | Sep → Nov 2025 | — | LG Chem | Completed | No outcome recorded |
| Phase 1 | NCT05105698 | Jan → Feb 2022 | — | LG Chem | Unknown | No outcome recorded |
| Phase 1 | NCT04544319 | Oct 2020 → Mar 2021 | type 2 diabetes mellitus | LG Chem | Unknown | No outcome recorded |
| Phase 1 | NCT03864432 | Jul → Oct 2019 | type 2 diabetes mellitus | LG Chem | Completed | No outcome recorded |
| Phase 1 | NCT03867942 | Mar → May 2019 | hyperlipidemia, type 2 diabetes mellitus | LG Chem | Unknown | No outcome recorded |
| Phase 1 | NCT03565458 | Apr → Aug 2018 | type 2 diabetes mellitus | LG Chem | Unknown | No outcome recorded |
| Phase 1 | NCT03355014 | Dec 2017 → Jan 2018 | — | LG Chem | Completed | No outcome recorded |
| Phase 1 | NCT02670070 | Mar → Apr 2016 | — | LG Life Sciences | Unknown | No outcome recorded |
| Phase 1 | NCT03310749 | Jan → May 2016 | type 2 diabetes mellitus | Stendhal Americas, S.A. | Completed | No outcome recorded |
| Phase 1 | NCT01595880 | Dec 2014 → Jan 2015 | — | LG Life Sciences | Completed | No outcome recorded |
| Phase 1 | NCT02056600 | Mar → Apr 2014 | — | LG Life Sciences | Completed | No outcome recorded |
| Phase 1 | NCT02004587 | Sep 2013 → May 2014 | — | LG Life Sciences | Completed | No outcome recorded |
| Phase 1 | NCT01825850 | Jun → Sep 2013 | — | LG Life Sciences | Completed | No outcome recorded |
| Phase 1 | NCT01823133 | Apr → May 2013 | — | LG Life Sciences | Completed | No outcome recorded |
| Phase 1 | NCT01768455 | Feb → Apr 2013 | — | LG Life Sciences | Completed | No outcome recorded |
| Phase 1 | NCT01747083 | Jan → Mar 2013 | type 2 diabetes mellitus | LG Life Sciences | Completed | No outcome recorded |
| Phase 1 | NCT01662674 | Oct → Nov 2012 | — | LG Life Sciences | Completed | No outcome recorded |
| Phase 1 | NCT01426399 | Aug → Nov 2011 | — | LG Life Sciences | Completed | No outcome recorded |
| Phase 1 | NCT01603238 | May 2011 | — | LG Life Sciences | Completed | No outcome recorded |
| Phase 1 | NCT01001013 | Feb → Jun 2009 | — | LG Life Sciences | Completed | No outcome recorded |
| Phase 310 trials | ||||||
| Phase 3 | NCT04255238 | Jun 2020 → May 2022 | type 2 diabetes mellitus | LG Chem | Unknown | No outcome recorded |
| Phase 3 | NCT02831361 | Oct 2016 → Feb 2018 | type 2 diabetes mellitus | LG Life Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02343926 | Dec 2014 → Apr 2016 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02089126 | Jun 2014 → Sep 2016 | type 2 diabetes mellitus | LG Life Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT02126358 | May 2014 → Mar 2016 | hyperlipidemia, type 2 diabetes mellitus | LG Life Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01990469 | Jan 2014 → Apr 2015 | type 2 diabetes mellitus | LG Life Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01968044 | Oct 2013 → Oct 2015 | — | LG Life Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01787396 | Apr 2013 → Mar 2015 | type 2 diabetes mellitus | LG Life Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01601990 | Dec 2009 → Mar 2011 | type 2 diabetes mellitus | LG Life Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01602003 | Dec 2009 → Jun 2011 | type 2 diabetes mellitus | LG Life Sciences | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT05663736 | Jan 2020 → Oct 2023 | — | Seoul National University Bundang Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03202563 | Aug 2017 → Jul 2018 | type 2 diabetes mellitus | LG Chem | Completed | No outcome recorded |
| Phase 4 | NCT02500329 | Sep 2014 → Dec 2015 | type 2 diabetes mellitus | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01890629 | May 2013 → Aug 2014 | type 2 diabetes mellitus | LG Life Sciences | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT04705506 | Feb 2017 → Mar 2019 | diabetic kidney disease | Bangkok Metropolitan Administration Medical College and Vajira Hospital | Completed | No outcome recorded |
| — | NCT02609815 | Nov 2015 → Mar 2021 | type 2 diabetes mellitus | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| — | NCT02186080 | Jul 2014 → Jul 2015 | type 2 diabetes mellitus | Seoul National University Hospital | Completed | No outcome recorded |
Also used as a comparator or background therapy in 5 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04070794 Comparator | Nov 2019 | type 2 diabetes mellitus | LG Chem | Unknown | No outcome recorded |
| Phase 1 | NCT02670018 Comparator | Aug → Dec 2015 | — | LG Life Sciences | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02250872 Comparator | Dec 2014 → Feb 2018 | cancer, cisplatin toxicity | Seoul National University Bundang Hospital | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03842267 Comparator | May 2019 → May 2021 | type 2 diabetes mellitus | LG Chem | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05194592 Comparator | Jan 2022 → Dec 2024 | type 2 diabetes mellitus | Wonju Severance Christian Hospital | Unknown | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 47 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gemigliptin | “Each component of Gemigliptin 50mg QD and Dapagliflozin 10mg QD” NCT04544319 ↗38“monolayer combination of Gemigliptin/Rosuvastatin 50/20mg” NCT03867942 ↗ |
| Known as | Gemigliptina | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707235 ↗ |
| Known as | Gemigliptine | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707235 ↗ |
| Known as | LC15-0444 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01601990 ↗ |
| Known as | LS15-0444 | “Drug: GEMIGLIPTIN LS15-0444” NCT02343926 ↗ |
| Known as | Zemiglo | “The patients assigned to the Gemigliptin group will take Zemiglo Pill 50mg for 6 months.” NCT05194592 ↗2“Reference drug: gemigliptin (Zemiglo) 50mg, Xigduo XR 10/1000 mg” NCT07333742 ↗ “Gemigliptin (Zemiglo) 50mg” NCT07399470 ↗ |
| Action | Inhibit | “LC15-0444, a newly developed selective dipeptidyl peptidase IV inhibitor” PMID 22192641 ↗ Jan 2012 |
| Modality | Small molecule | — CHEMBL3707235 ↗ |
| Route | Oral | “Pharmacokinetic Drug Interaction Between LC15-0444 and Pioglitazone After Oral Administration in Healthy Male Subjects” NCT01001013 ↗ |
| Target | DPP4 | “Gemigliptin is a selective DPP4 inhibitor used to treat type 2 diabetes.” PMID 25350224 ↗ Nov 2014 |